IL-2 treatment is currently being tested to treat a variety of inflammatory and autoimmune diseases by targeting Tregs (46), however, several studies have shown that even using very low doses IL-2 treatment also activates and expands the frequency CD56bright NK cells in blood (44, 47) but to date no data is available on whether a similar expansion is also seen in the LNs. Here, IL2 is linked to autoimmune disease.